Analyst Josh Jennings from TD Cowen reiterated a Buy rating on Establishment Labs Holdings and keeping the price target at $60.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that highlight the growing adoption and demand for Establishment Labs Holdings’ Motiva implants. A key factor is the positive feedback from a high-volume US plastic surgeon, who has increasingly shifted to using Motiva implants due to their superior safety and efficacy profile, natural feel, and strong patient preference. The surgeon’s experience indicates that patients consistently choose Motiva over other options, even in markets sensitive to pricing, suggesting a robust demand for the product.
Another reason for the Buy rating is the innovative nature of Motiva implants, which are seen as setting a new standard in breast aesthetics. The surgeon noted that the implants’ design allows for advantageous clinical outcomes, such as the return to pre-pectoral placement, with minimal learning curve for surgeons. Additionally, the Preserve/Mia platform is viewed as a significant tool for expanding practices by attracting new patient segments. These factors collectively underscore the potential for Establishment Labs to capture a larger market share and drive future growth.
In another report released on June 26, Mizuho Securities also maintained a Buy rating on the stock with a $70.00 price target.